The Norwegian Bliss will no longer offer the “Jersey Boys” Broadway show, according to an update shared by Norwegian Cruise Line.
In a statement sent to guests set to board the ship, the company said that the musical performance will be replaced by a host of performances.
“As we prepare for your upcoming voyage, we want to share a quick update about our entertainment lineup. ‘Jersey Boys’ will be concluding its run in the Bliss Theater,” Norwegian said in the letter issued in late January.
“While we know this change may come as a disappointment, we are refreshing our offerings with a rotating collection of performers chosen to surprise, delight and keep your evenings just as memorable,” the company continued.
According to Norwegian, the lineup includes comedians, magicians, jugglers and other specialty acts “who each bring their own spark to the stage.”
Passengers are asked to make reservations for the new shows and performances onboard by visiting the box office, using the NCL app, or using interactive TV screens.
“We’re here for you every step of the way, and we’re committed to making this cruise not just enjoyable but unforgettable,” the company added.
Cruise Industry News, Norwegian is phasing out Broadway productions onboard its fleet.
The change was initially announced in mid-2023 as part of an update to the entertainment and theater offerings onboard its vessels.
At the time, the company said that the change aimed at “elevating the offerings” in order to “exceed the expectations” of guests.
Norwegian later said, in 2024, that the revamped program meant an increased ship return on investment (ROI).
The new lineup includes shorter, high-energy shows produced internally in Tampa with fewer cast members, the company explained.
In addition to reducing the number of revenue cabins taken up by Broadway-style cast members, the move also reduced licensing fees required to license the former titles.
Norwegian also said that the highest-rated shows in the fleet at the time were the smallest shows from a cast perspective.